Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity

被引:48
作者
Englyst, Nicola A. [2 ]
Horsfield, Gill [1 ]
Kwan, Joseph [3 ]
Byrne, Christopher D. [2 ]
机构
[1] Southampton Gen Hosp, Inst Dev Sci, Wellcome Trust Clin Res Facil, Southampton SO16 6YD, Hants, England
[2] Univ Southampton, Endocrinol & Metab Unit, Dev Origins Hlth & Dis Div, Southampton, Hants, England
[3] Royal Bournemouth Hosp, Dept Med Elderly, Bournemouth, Dorset, England
关键词
aspirin resistance; IL-6; lacunar; platelets; stroke;
D O I
10.1038/jcbfm.2008.9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this study was to investigate the relationship between aspirin resistance, ischaemic stroke subtype, stroke severity, and inflammatory cytokines. Aspirin resistance was assessed by thrombelastography in 45 people with ischaemic stroke and 25 controls. Plasma interleukin (IL)-6 was measured. Stroke severity was assessed using the modified Rankin scale and National Institute of Health Stroke Score within 72 h of stroke. Aspirin resistance was more common in the stroke than the control group (67% versus 40%, P=0.028), and within the stroke group the aspirin-resistant group had a higher Rankin score (4.0 versus 2.0, P=0.013). Aspirin resistance was greater in lacunar than embolic strokes ( platelet activation 79% versus 59%, P=0.020). The stroke aspirin-resistant group had higher levels of IL-6 than the stroke aspirin-sensitive group (2.4 +/- 1 versus 1.8 +/- 0.9 ng/mL, P=0.037). Using multivariate analysis, we examined the interrelationships between aspirin resistance, IL-6, and stroke severity. These analyses showed that IL-6 was independently associated with stroke severity as the outcome (B=3.738, P=0.036), and aspirin resistance was independently associated with IL-6 (B=0.765, P=0.005) as the outcome. In conclusion, aspirin resistance is related to stroke severity and aspirin resistance is more common in lacunar strokes than embolic strokes.
引用
收藏
页码:1196 / 1203
页数:8
相关论文
共 42 条
[1]   Quantifying the effect of antiplatelet therapy -: A comparison of the platelet function Analyzer (PFA-100®) and modified thromboelastography (mTEG®) with lightt transmission platelet aggregometry [J].
Agarwal, Seema ;
Coakely, Margaret ;
Reddy, Kalpana ;
Riddell, Anne ;
Mallett, Susan .
ANESTHESIOLOGY, 2006, 105 (04) :676-683
[2]   The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? [J].
Altman R. ;
Luciardi H.L. ;
Muntaner J. ;
Herrera R.N. .
Thrombosis Journal, 2 (1)
[3]   Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary analysis of the GAIN International trial [J].
Aslanyan, S ;
Weir, CJ ;
Diener, HC ;
Kaste, M ;
Lees, KR .
EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 (01) :49-53
[4]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[5]   CLASSIFICATION AND NATURAL-HISTORY OF CLINICALLY IDENTIFIABLE SUBTYPES OF CEREBRAL INFARCTION [J].
BAMFORD, J ;
SANDERCOCK, P ;
DENNIS, M ;
BURN, J ;
WARLOW, C .
LANCET, 1991, 337 (8756) :1521-1526
[6]   INTERLEUKIN-6 AND INTERLEUKIN-1 RECEPTOR ANTAGONIST IN ACUTE STROKE [J].
BEAMER, NB ;
COULL, BM ;
CLARK, WM ;
HAZEL, JS ;
SILBERGER, JR .
ANNALS OF NEUROLOGY, 1995, 37 (06) :800-805
[7]   MEASUREMENTS OF ACUTE CEREBRAL INFARCTION - A CLINICAL EXAMINATION SCALE [J].
BROTT, T ;
ADAMS, HP ;
OLINGER, CP ;
MARLER, JR ;
BARSAN, WG ;
BILLER, J ;
SPILKER, J ;
HOLLERAN, R ;
EBERLE, R ;
HERTZBERG, V ;
RORICK, M ;
MOOMAW, CJ ;
WALKER, M .
STROKE, 1989, 20 (07) :864-870
[8]  
BUCHANAN MR, 1995, CAN J CARDIOL, V11, P221
[9]   MODULATION OF HUMAN ENDOTHELIAL-CELL PERMEABILITY BY COMBINATIONS OF THE CYTOKINES INTERLEUKIN-1 ALPHA/BETA, TUMOR-NECROSIS-FACTOR-ALPHA AND INTERFERON-GAMMA [J].
BURKEGAFFNEY, A ;
KEENAN, AK .
IMMUNOPHARMACOLOGY, 1993, 25 (01) :1-9
[10]  
Carlson NG, 1999, J IMMUNOL, V163, P3963